Enfortumab Vedotin-EJFV - Save Up to 90% with Coupons, Discounts & Assistance Programs
We found the following savings options for Enfortumab Vedotin-EJFV. Compare Rx discount cards, drug coupons, patient assistance programs, Canadian online pharmacy prices, and telehealth options side by side. Pay as little as $0 per fill at 65,000+ pharmacies. Works whether you're insured, uninsured, or underinsured.


Start Saving Today!
Lower the Cost of Your Enfortumab Vedotin-EJFV Prescription
More great savings
View Related Brands
MEDICAL INFORMATION
Enfortumab Vedotin-EJFV Key Facts
What dosages is Enfortumab Vedotin-EJFV available in?
Enfortumab Vedotin-EJFV is available as an injection that contains 20 mg or 30 mg of Enfortumab Vedotin-EJFV.
What is Enfortumab Vedotin-EJFV used for?
Enfortumab Vedotin-EJFV V is a Nectin-4-directed antibody and microtubule inhibitor conjugate indicated:
In combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer. As a single agent for the treatment of adult patients with locally advanced or metastatic urothelial cancer who: Have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinumcontaining chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
How does Enfortumab Vedotin-EJFV work?
Enfortumab Vedotin-EJFV works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells.
How do I take Enfortumab Vedotin-EJFV?
The recommended dose of Enfortumab Vedotin-EJFV in combination with
pembrolizumab is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicity. The recommended dose of Enfortumab Vedotin-EJFV as a single agent is 1.25 mg/kg (up to a maximum dose of 125 mg) given as an intravenous infusion over 30 minutes on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
Is it safe for me to take Enfortumab Vedotin-EJFV?
Enfortumab Vedotin-EJFV is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.
Enfortumab Vedotin-EJFV Common Side Effects
Common side effects of Enfortumab Vedotin-EJFV when used alone:
- Increased sugar (glucose) in the blood
- Changes in liver and kidney function tests
- Decreased white blood cell, red blood cell, and platelet counts
- Rash
- Tiredness
- Numbness or tingling in your hands or feet
- Decreased protein (albumin), sodium, and phosphate in the blood
- Hair loss
- Decreased appetite
- Diarrhea
- Nausea
- Itching
- Increased uric acid in the blood
- Dry eye
- Change in sense of taste
- Constipation
- Increased lipase (a test done to check your pancreas)
Enfortumab Vedotin-EJFV Serious Side Effects
Serious side effects are rare with Enfortumab Vedotin-EJFV. Contact your healthcare provider immediately if you experience any of the following.
- Skin reactions
- High blood sugar (hyperglycemia)
- Lung problems
- Nerve problems
- Eye problems
- Leakage of Enfortumab Vedotin-EJFV out of your vein into the tissues around your infusion site (extravasation)
Effects of other drugs, drug classes and over-the-counter products on Enfortumab Vedotin-EJFV
The following medications may interact with Enfortumab Vedotin-EJFV:
- Concomitant use of dual P-gp and strong CYP3A4 inhibitors with Enfortumab Vedotin-EJFV may increase the exposure to monomethyl auristatin E (MMAE)
Who makes Enfortumab Vedotin-EJFV?
Various FDA-approved generic manufacturers
Is Enfortumab Vedotin-EJFV safe in pregnancy?
Enfortumab Vedotin-EJFV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Enfortumab Vedotin-EJFV. Females who are able to become pregnant: Your healthcare provider should do a pregnancy test before you start treatment with Enfortumab Vedotin-EJFV.
You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of Enfortumab Vedotin-EJFV.
Males with a female sexual partner who is able to become pregnant: If your female partner is pregnant, Enfortumab Vedotin-EJFV can harm the unborn baby. You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of Enfortumab Vedotin-EJFV
What is the brand name for Enfortumab Vedotin-EJFV?
Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
OUR CUSTOMERS VIEW
What Customers Love About Our Service
We want everyone to be happy and healthy, that’s what keeps us going. Read what some of them have to say about us.
Medicines Experts
Meet Our Medical Team
We are a broad skilled and passionate group of clinicians with experience of operating in health systems in the United Kingdom & United States. Providing excellent care and advice is at the heart of everything we do. You can read more about our medical team by visiting the medical team page or learn more about how we curate content by visiting our editorial process

























